866-997-4948(US-Canada Toll Free)

DURECT Corporation (DRRX) - Product Pipeline Analysis

Published By :

GlobalData

Published Date : Nov 2012

Category :

Surgical Equipment

No. of Pages : 37 Pages


DURECT Corporation (Durect) is a pharmaceutical company engaged in the development of pharmaceutical systems based on proprietary drug delivery technology platforms to treat chronic debilitating diseases. It is also involved in the development of biotechnology products. Currently, the company markets two products, namely, Alzet osmotic pump and Lactel biodegradable polymer. Durect has five drug delivery technology platforms, namely, SABER delivery system, ORADUR delivery system, TRANSDUR delivery system, DURIN biodegradable implant and MICRODUR biodegradable microparticulate. The company operates in North America, Europe and Asia. Durect is headquartered in California, the US.

The company aims to develop proprietary products in chronic care areas by expanding its technology platforms through both organic and inorganic growth strategies.

This report is a source for data, analysis and actionable intelligence on the DURECT Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

  • Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
  • Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
  • Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
  • Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
  • Data on relevant clinical trials and product patent details, wherever applicable.
  • Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
  • Design and develop your product development, marketing and sales strategies.
  • Exploit M&A opportunities by identifying market players with the most innovative pipeline.
  • Develop market-entry and market expansion strategies.
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Develop competition strategies by identifying the status and likely launch of your competitors pipeline products through review of the clinical trials, stage and phase of development, etc.Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.
Table of Content

Table of Contents 2
List of Tables 3
List of Figures 3

DURECT Corporation - Business Description 4

Key Facts 5
DURECT Corporation - Major Products and Services 6
DURECT Corporation Pipeline Products by Equipment Type 7
DURECT Corporation Pipeline Products by Development Stage 9
DURECT Corporation Pipeline Products by Therapy Area 11
DURECT Corporation Pipeline Products by Trial Phase 13
Eladur 15
Eladur Product Status 15
Eladur Product Description 15
POSIDUR 16
POSIDUR Product Status 16
POSIDUR Product Description 16
POSIDUR Clinical Trial 16
TRANSDUR Patch 19
TRANSDUR Patch Product Status 19
TRANSDUR Patch Product Description 19
TRANSDUR Patch Clinical Trial 19
TRANSDUR Patch Product Patent Details 27
DURECT Corporation - Key Competitors 30
DURECT Corporation - Key Employees 31
DURECT Corporation - Key Employee Biographies 32
DURECT Corporation - Locations And Subsidiaries 33
Head Office 33
Recent Developments 34
DURECT Corporation, Recent Developments 34
Nov 05, 2012: Durect Reports Revenue Of $3.8m In Q3 2012 34
Aug 06, 2012: DURECT Reports Revenue Of $4.8m In Q2 2012 34
May 03, 2012: DURECT Reports Revenue Of $41.2m In Q1 2012 34
Mar 01, 2012: DURECT Reports Revenue Of $33.5m In 2011 34
Nov 03, 2011: DURECT Reports Revenues Of $8.1m In Q3 2011 35
Aug 04, 2011: DURECT Reports Total Revenues Of $7.8m In Q2 2011 35
Jun 02, 2011: DURECT Announces Resignation Of Chief Medical Officer 35
May 05, 2011: DURECT Reports Total Revenues Of $8.6m In Q1 2011 36
Mar 02, 2011: DURECT Reports Total Revenues Of $31.6m In 2010 36
Mar 02, 2011: DURECT Reports Net Loss Of $5.3m For Q4 2010 36

Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Table


DURECT Corporation, Key Facts 1
DURECT Corporation Key Pipeline Products by Equipment Type 1
DURECT Corporation Key Pipeline Products by Therapy Area 1
DURECT Corporation Key Pipeline Products by Development Stage 1
DURECT Corporation Key Pipeline Products by Trial Phase 1
DURECT Corporation, Key Facts 5
DURECT Corporation, Major Products and Services 6
DURECT Corporation Number of Pipeline Products by Equipment Type 7
DURECT Corporation Pipeline Products by Equipment Type 8
DURECT Corporation Number of Pipeline Products by Development Stage 9
DURECT Corporation Pipeline Products by Development Stage 10
DURECT Corporation Number of Pipeline Products by Therapy Area 11
DURECT Corporation Pipeline Products by Therapy Area 12
DURECT Corporation Number of Pipeline Products by Trial Phase 13
DURECT Corporation Pipeline Products by Trial Phase 14
Eladur - Product Status 15
Eladur - Product Description 15
POSIDUR - Product Status 16
POSIDUR - Product Description 16
POSIDUR - DURECT\'s Phase II Clinical Trial For Post-Operative Pain Relief Depot 16
POSIDUR - DURECT Announces Positive Clinical Results for its Post-operative Pain Relief Depot using the SABER Delivery System 17
TRANSDUR Patch - Product Status 19
TRANSDUR Patch - Product Description 19
TRANSDUR Patch - Clinical Trial For A New Proprietary Transdermal Sufentanil Product 19
TRANSDUR Patch - Phase II program For TRANSDUR-Sufentanil 20
TRANSDUR Patch - Efficacy Study Of TRANSDUR Sufentanil To Evaluate Dose Response Rate For The Treatment Of Chronic Pain 21
TRANSDUR Patch - Efficacy Study Of TRANSDUR-Sufentanil Showing Reduction In Pain Scores After The Therapy 21
TRANSDUR Patch - DURECT\'\'s Transdermal Sufentanil Patch Study 23
TRANSDUR Patch - A Randomized, Double-Blind, Placebo Controlled, Two-Way Cross-Over Study Of Analgesic Efficacy Of Bupivacaine Transdermal Therapeutic System In Patients With Post-Herpetic Neuralgia 24
TRANSDUR Patch - A Randomized, Double-Blind, Placebo-Controlled, Trial Of A Three-Day Bupivacaine Patch (ELADUR) In Patients With Post-Herpetic Neuralgia 25
TRANSDUR Patch - Patent Details1 27
TRANSDUR Patch - Patent Details2 28
TRANSDUR Patch - Patent Details3 28
TRANSDUR Patch - Patent Details4 29
TRANSDUR Patch - Patent Details5 29
DURECT Corporation, Key Employees 31
DURECT Corporation, Key Employee Biographies 32

List of Chart


DURECT Corporation Key Pipeline Products by Equipment Type 1
DURECT Corporation Pipeline Products by Equipment Type 7
DURECT Corporation Pipeline Products by Development Stage 9
DURECT Corporation Pipeline Products by Therapy Area 11
DURECT Corporation Pipeline Products by Trial Phase 13

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *